Displaying all 635 funding opportunities ($600,438,295,000) that matched your search: [Only Active Grants] AND [CFDA: 93.279 - Drug Abuse and Addiction Research Programs] AND [Sort By Due Date Soonest First]
The purpose of the Academic Research Enhancement Award (AREA) program is to stimulate research in educational institutions that provide baccalaureate or advanced degrees for a significant number of the Nation's research scientists, but that have not been major recipients of NIH support. These AREA grants create opportunities for scientists and institutions otherwise unlikely to participate extensively in NIH programs, to contribute to the Nation's biomedical and behavioral research effort. AREA grants are intended to support small-scale health-related research projects proposed by faculty members of eligible, domestic institutions. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. This funding opportunity will use the R15 mechanism. Eligible organizations include all public or private institutions and components of institutions such as health professional schools/colleges and other academic components of domestic institutions offering baccalaureate or advanced degrees in the sciences related to health, except those that have received research grants and/or cooperative agreements from the NIH totaling more than $3 million per year (in both direct and indirect costs) in each of four (4) or more of the last seven (7) years.
This funding opportunity provides updated guidelines for National Institutes of Health (NIH) support of conferences and scientific meetings. Because the nature and scope of the proposed activities will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the number of applications, quality, duration, and costs of the applications received. This funding opportunity announcement (FOA) will use the NIH conference grant (R13) and conference cooperative agreement (U13) award mechanisms.
- This Funding Opportunity Announcement (FOA), issued as an initiative of the trans-NIH Bioengineering Consortium (BECON) on behalf of the participating Institutes and Centers, invites Small Business Technology Transfer (STTR) grant applications for projects for developing and applying nanotechnology to biomedicine. Nanotechnology is defined as the creation of functional materials, devices and systems through control of matter at the scale of 1 to 100 nanometers, and the exploitation of novel properties and phenomena at the same scale. Nanotechnology is emerging as a field critical for enabling essential breakthroughs that may have tremendous potential for affecting biomedicine. Moreover, nanotechnologies developed in the next several years may well form the foundation of significant commercial platforms that shift the paradigms of clinical applications. - Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism numbers, quality, duration, and costs of the applications received. - This funding opportunity will use the STTR (R41/R42) grant mechanism. - This funding opportunity will be run in parallel with a FOA of identical scientific scope, ?Manufacturing Processes of Medical, Dental, and Biological Technologies" (PA-06-009) that will utilize the Small Business Innovation Research (SBIR [R43/R44]) grant mechanism. - Only United States SBCs are eligible to submit SBIR applications. A SBC is one that, on the date of award for both Phase I and Phase II funding agreements, meets ALL of the criteria as described in Section III. I.A. - Any individual with the skills, knowledge, and resources necessary to carry out the proposed research is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as
- The participating institutes of the National Institutes of Health invite the small business community to apply cutting edge-technology to develop new approaches and chemical modifications that will increase the long term stability, delivery and targeting of siRNAs in cells and tissues for laboratory and therapeutic applications. The number of awards made under this solicitation will depend on the overall scientific merit of the applications and the availability of funds. - This PA uses the STTR (R41/R42) mechanisms. - This funding opportunity will utilize the Small Business Technology Transfer (STTR) mechanism, but will be run in parallel with a program announcement of identical scientific scope (PA-06-003) that will utilize the Small Business Innovation Research (SBIR) grant mechanism. - Only United States SBCs are eligible to submit SBIR applications. A SBC is one that, on the date of award for both Phase I and Phase II funding agreements, meets ALL of the criteria as described in Section III. I.A. - Any individual with the skills, knowledge, and resources necessary to carry out the proposed research is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH programs. On an SBIR application, the Project Director/Principal Investigator (PD/PI) must have his/her primary employment (more than 50%) with the SBC at the time of award and for the duration of the project. - Applicant SBCs may submit more than one application, provided each application is scientifically distinct. - See Section IV.1 for application materials. The application instructions for this Funding Opportunity Announcement (FOA) are located at the following links: http://grants.nih.gov/grants/funding/424/SF424_RR_Guide_SBIR_STTR.doc (MS Word) and http://grants.nih.gov/grants/funding/424/SF424_RR_Guide_SBIR_STTR.pdf (PDF). Applicants are ...
- The participating institutes of the National Institutes of Health invite the small business community to apply cutting edge-technology to develop new approaches and chemical modifications that will increase the long term stability, delivery and targeting of siRNAs in cells and tissues for laboratory and therapeutic applications. - The number of awards made under this solicitation will depend on the overall scientific merit of the applications and the availability of funds. - This PA uses the SBIR mechanisms. Only small business concerns are eligible to submit applications. - This funding opportunity will utilize the Small Business Innovation Research (SBIR) mechanism, but will be run in parallel with a program announcement of identical scientific scope (PA-06-004) that will utilize the Small Business Technology Transfer (STTR) grant mechanism. - Only United States SBCs are eligible to submit SBIR applications. A SBC is one that, on the date of award for both Phase I and Phase II funding agreements, meets ALL of the criteria as described in Section III. I.A. - Any individual with the skills, knowledge, and resources necessary to carry out the proposed research is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH programs. On an SBIR application, the Project Director/Principal Investigator (PD/PI) must have his/her primary employment (more than 50 percent) with the SBC at the time of award and for the duration of the project. - Applicant SBCs may submit more than one application, provided each application is scientifically distinct. - See Section IV.1 for application materials. The application instructions for this Funding Opportunity Announcement (FOA) are located at the following links: http://grants.nih.gov/grants/funding/424/SF424_RR_Guide_SBIR_STTR.doc (MS Word) ...
This initiative is intended to stimulate the commercial development of novel radioligands for positron emission tomography (PET) and single photon emission computed tomography (SPECT) imaging in human brain, and to incorporate pilot or clinical feasibility evaluation in pre-clinical studies, model development, or clinical studies. The NIH institutes listed in this FOA are specifically interested in the development of radioligands for molecular targets (e.g., receptors, cell adhesion molecules, intracellular messengers, and disease related proteins) that are of broad interest to the scientific community. These radiotracers will be used for neuroimaging as well as potential biological markers and surrogate endpoints for translational and clinical research, drug discovery and development, and clinical trials. Also appropriate for this FOA are applications proposing research and development of new technologies for radiotracer development.
This initiative is intended to stimulate the commercial development of novel radioligands for positron emission tomography (PET) and single photon emission computed tomography (SPECT) imaging in human brain, and to incorporate pilot or clinical feasibility evaluation in pre-clinical studies, model development, or clinical studies. The NIH institutes listed in this FOA are specifically interested in the development of radioligands for molecular targets (e.g., receptors, cell adhesion molecules, intracellular messengers, and disease related proteins) that are of broad interest to the scientific community. These radiotracers will be used for neuroimaging as well as potential biological markers and surrogate endpoints for translational and clinical research, drug discovery and development, and clinical trials. Also appropriate for this FOA are applications proposing research and development of new technologies for radiotracer development.
On February 26, 2004, Executive Order 13329 (http://a257.g.akamaitech.net/7/257/2422/14mar20010800/edocket.access.gpo.gov/2004/pdf/04-4436.pdf) was signed by President George W. Bush requiring SBIR/STTR agencies, to the extent permitted by law and in a manner consistent with the mission of the Department, to give high priority within the SBIR and STTR programs to manufacturing-related research and development (R&D). In response to this Executive Order, NIH is expanding its focus by encouraging eligible United States small business concerns to submit SBIR Phase I, Phase II, and Fast-Track grant applications whose biomedical research is related to advanced processing, manufacturing processes, equipment and systems, and manufacturing workforce skills and protection.
On February 26, 2004, Executive Order 13329 (http://a257.g.akamaitech.net/7/257/2422/14mar20010800/edocket.access.gpo.gov/2004/pdf/04-4436.pdf) was signed by President George W. Bush requiring agencies with Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, to the extent permitted by law and in a manner consistent with the mission of the Department, to give high priority within the SBIR and STTR programs to manufacturing-related research and development (R&D). In response to this Executive Order, NIH is expanding its focus by encouraging eligible United States small business concerns to submit STTR Phase I, Phase II, and Fast-Track grant applications whose biomedical research is related to advanced processing, manufacturing processes, equipment and systems, and manufacturing workforce skills and protection.
- This Funding Opportunity Announcement (FOA), issued as an initiative of the trans-NIH Bioengineering Consortium (BECON) on behalf of the participating Institutes and Centers, invites Small Business Innovation Research (SBIR) grant applications for projects for developing and applying nanotechnology to biomedicine. Nanotechnology is defined as the creation of functional materials, devices and systems through control of matter at the scale of 1 to 100 nanometers, and the exploitation of novel properties and phenomena at the same scale. Nanotechnology is emerging as a field critical for enabling essential breakthroughs that may have tremendous potential for affecting biomedicine. Moreover, nanotechnologies developed in the next several years may well form the foundation of significant commercial platforms that shift the paradigms of clinical applications. - Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism numbers, quality, duration, and costs of the applications received. - This funding opportunity will use the SBIR (R43/R44) grant mechanisms. - This funding opportunity will be run in parallel with a program announcement of identical scientific scope (PA-06-008) that will utilize the Small Business Technology Transfer (STTR) grant mechanism. - Only United States SBCs are eligible to submit SBIR applications. A SBC is one that, on the date of award for both Phase I and Phase II funding agreements, meets ALL of the criteria as described in Section III.I.A. - Any individual with the skills, knowledge, and resources necessary to carry out the proposed research is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to ...
The purpose of this FOA from NIH is to invite eligible United States small business concerns (SBCs) to submit STTR Phase I, Phase II, and Fast-Track grant applications through Grants.gov. (CDC and FDA do not accept STTR grant applications).
The purpose of this FOA from NIH, CDC, and FDA is to invite eligible United States small business concerns (SBCs) to submit SBIR Phase I, Phase II, and Fast-Track grant applications through Grants.gov. SBIR Fast-Track grant applications are accepted by the NIH ONLY.
The National Institute of Mental Health (NIMH), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute on Drug Abuse (NIDA), National Institute of Biomedical Imaging and Bioengineering (NIBIB), and National Institute on Neurological Disorders and Stroke (NINDS) request research grant applications to study neuroimmune molecules and mechanisms involved in regulating normal and pathological central nervous system (CNS) function. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism numbers, quality, duration, and costs of the applications received. This PA will use the NIH R01, R21, and R03 award mechanisms. Applications may be submitted by domestic or foreign, for-profit or non-prof! it organizations, public or private institutions, such as universities, colleges, hospitals, and laboratories; units of State and local governments; eligible agencies of the Federal government. Any individual with the skills, knowledge, and resources necessary to carry out the proposed research is invited to work with their institution to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH programs. There is no limit on the number of applications that may be submitted. Applications must be prepared using the PHS 398 research grant application instructions and forms (rev. 5/2001).The PHS 398 is available at http://grants.nih.gov/grants/funding/phs398/phs398.html in an interactive format. For further assistance contact GrantsInfo, Telephone (301) 435-0714, Email: GrantsInfo@nih.gov.
- As summarized in the 2003 National Sleep Disorders Research Plan (http://www.nhlbi.nih.gov/health/prof/sleep/res_plan/index.html), multiple scientific areas in sleep and sleep disorders need additional research. In addition, therapy for a number of sleep disorders remains suboptimal, and the research workforce addressing sleep science is insufficient. The NHLBI, National Center on Sleep Disorders Research, and co-sponsoring member Institutes and Centers of the Trans-NIH Sleep Research Coordinating Committee therefore invite submission of grant applications proposing research to advance biomedical knowledge related to sleep or sleep disorders, improve understanding of the neurobiology or functions of sleep over the life-span, enhance timely diagnosis and effective treatment for individuals affected by sleep-related disorders, or implement and evaluate innovative community-based public health education and intervention programs. Because the nature and ! scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism, numbers, quality, duration , and costs of the applications received. - This PA will use the NIH R01and R21 award mechanisms. - Eligible organizations include institutions with any of the following characteristics: - For-profit or non-profit organizations - Public or private institutions, such as universities, colleges, hospitals, and laboratories - Units of State and local governments - Eligible agencies of the Federal government - Domestic or foreign institutions/organizations - Faith-based or community-based organizations - Eligible principal investigators include individual with the skills, knowledge, and resources necessary to carry out the proposed research. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to ...
- The National Institutes of Health (NIH), through the participating Institutes, Centers, and Offices listed above, invite applications in support of research on mind-body interactions and health. "Mind-body interactions and health" refers to the relationships among cognitions, emotions, personality, social relationships, and health. A central goal of this program is to encourage interdisciplinary collaboration and innovation towards understanding the processes underlying mind-body interactions and health as well as towards the application of such basic knowledge to interventions and clinical practice in the promotion of health and the prevention or treatment of disease and disabilities. - The total amount to be awarded depends on the scientific merit of applications and the funds available at the participating NIH Institutes/Centers. - The anticipated number of awards is contingent on their scientific merit and the funds available in the general funding pool of the participating NIH Institutes/Centers. - The type of mechanism is the Research (R01) Award. NIH Institutes and Centers may also accept applications for other mechanisms. - Eligible organizations include for-profit and not-for-profit, public or private organizations, units of state and local governments, eligible agencies of the Federal Government, domestic or foreign institutions/organizations, faith-based or community-based organizations, and Native American tribal organizations. - Eligible principal investigators are any individuals with the skills, knowledge, and resources necessary to carry out the proposed research. - The number of applications each applicant may submit is unrestricted. - The PHS 398 application instructions are available at http://grants.nih.gov/grants/funding/phs398/phs398.html in an interactive format. For further assistance contact GrantsInfo, Telephone 301-435-0714, E-mail: GrantsInfo@nih.gov.
The NIH hereby notifies Principal Investigators holding specific types of NIH research grants (listed in the full announcement) that funds are available for administrative supplements to improve the diversity of the research workforce by supporting and recruiting students, postdoctorates, and eligible investigators from groups that have been shown to be underrepresented. Although the administrative supplements supported under this program provide funding for less than one percent of all individuals involved in NIH supported research, the NIH has found these awards to be an effective means of encouraging institutions to recruit from currently underrepresented groups. Administrative supplements must support work within the scope of the original project.
The NIDA, NIAAA, and the NIMH invite research grant applications to services research on co-occurring mental illness, alcohol and/or drug abuse, and commonly co-occurring medical conditions. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism numbers, quality, duration, and costs of the applications received. This PA will use the NIH R01, R03, and R21 award mechanism(s). Applications may be submitted by for-profit or non-profit organizations, public or private institutions, such as universities, colleges, hospitals, and laboratories; units of State and local governments; eligible agencies of the Federal government ; and Faith-based or community-based domestic institutions or organizations. Any individual with the skills, knowledge, and resources necessary to carry out the proposed research is invited to work with their institution to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH programs. There is no limit on the number of applications that may be submitted.
This PA replaces PA-01-072. The National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Drug Abuse (NIDA), and National Institute of Alcohol Abuse and Alcoholism (NIAAA) invite research grant applications through this Program Announcement (PA) to support research focused on determining the pathogenic mechanisms involved in Human Immunodeficiency Virus (HIV)-1 associated neurobehavioral and neurological dysfunction in domestic and international settings. The objective of this cooperative effort is to foster investigations that will provide the foundation for the rapid development of therapeutic interventions to prevent and treat the effects of HIV-1 on the central nervous system (CNS). Applications ranging from basic research to clinical diagnosis and treatment are of interest. Multidisciplinary research teams and collaborative alliances are encouraged but not required.
This PA supersedes PA-01-048, "Prescription Drug Abuse," issued on February 12, 2001 in the NIH Guide for Grants and Contracts at http://grants.nih.gov/grants/guide/pa-files/PA-01-048.html. In revising and reissuing this PA, NIDA continues to encourage research aimed at understanding and reducing prescription drug abuse while supporting appropriate medical use of therapeutic agents with abuse liability. To promote the Nations health, research is needed to understand the factors contributing to prescription drug abuse, to characterize the adverse medical, behavioral, and social consequences associated with this abuse, and to develop effective prevention and service delivery approaches and behavioral and pharmacological treatments. Applications to address this issue are encouraged across a broad range of experimental approaches including basic, clinical, epidemiological, prevention, and treatment studies.
In September 2003, the National Institute on Drug Abuse (NIDA) and the Office of the Directors Office of Dietary Supplements (ODS) came together and supported a workshop entitled Psychoactive Botanical Products. The presentations and ensuing discussion illustrated how little the scientific community currently knows about the chemistry, biology, pharmacology, and behavioral effects of psychoactive botanical (or natural) products and thus this workshop served to identify gaps in our knowledge outlined in this announcement. A summary for this workshop can be found at: http://www.drugabuse.gov/whatsnew/meetings/psychoactivemtgsumm.html. Under this PA, NIDA, ODS, and the National Institute of Mental Health (NIMH), invite research grant applications that characterize the chemistry, psychopharmacology, and/or toxicology of acute and chronic exposure to psychoactive natural products, as well as the transition in the use of these products to licit or illicit drugs of abuse. For the purposes of this PA, psychoactive natural products are defined as fungus- or plant-derived products that are taken primarily for their effects on the central nervous system (e.g., stimulant, depressant, and/or hallucinogenic effects), rather than for treatment, medicinal or therapeutic effects.
